Gilead Sciences | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD 5.72B 1.98B 2025-06
Agios Pharmaceuticals USD -127056000 20.43M 2025-06
ALKERMES USD 92.98M 79.19M 2025-06
Alnylam Pharmaceuticals USD -16199000 34.28M 2025-06
Amgen USD 1.29B 1.02B 2025-03
Biogen USD 851.8M 540.6M 2025-06
BioMarin Pharmaceutical USD 276.89M 52.99M 2025-06
Bristol-Myers Squibb USD 3.77B 366M 2025-06
Eli Lilly USD 7.02B 1.61B 2025-06
Gilead Sciences USD 2.7B 467M 2025-06
GlaxoSmithKline GBP 2.02B 193M 2025-06
Glaxosmithkline GBP 702M 513M 2024-12
Incyte USD 310.82M 105.66M 2025-06
J&J USD 6.94B 6.69B 2025-06
Merck USD 6.36B 494M 2025-06
Moderna USD -907000000 143M 2025-06
Neurocrine Biosciences USD 145.6M 121.9M 2025-06
Novartis USD 4.86B 201M 2025-06
Pfizer USD 2.6B 1.06B 2025-06
PTC Therapeutics USD -34858000 1.01B 2025-06
Regeneron Pharmaceuticals USD 1.08B 487.8M 2025-06
Sanofi EUR 1.71B 573M 2025-06
Sarepta Therapeutics USD 115.58M 415.96M 2025-06
United Therapeutics USD 276.9M 105.9M 2025-06
Vertex Pharmaceuticals USD 1.15B 123.1M 2025-06


Gilead Sciences Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.